Reddy, K.R., Kumari, P., Vinay, K., Singh, J., Chauhan, B.S., Kumar, P., Srikrishna, S., Kumar, D., Mishra, M., Singaravel, M., Prasad, N.K., Anuraag, N.S., Sahni, C., Sharma, S. (2024). Safety Study and Compositional Analysis of the Svarnvir-IV Tablet With Special Reference to Its Therapeutic Utility in SARS-CoV-2.  Cureus 16(12): e75438.

FBrf0261444

Research paper

Aim Traditional Ayurvedic herbo-mineral medicines have proven their potential in managing COVID-19. Cell-based assays of the Svarnvir-IV tablet demonstrated the virucidal activity against SARS-CoV-2 and its therapeutic action, along with safety in cytotoxicity, has been proved. In the present study, in vivo, safety profile and compositional analysis of the Svarnvir-IV tablet were performed. Methods The safety and potency of the Svarnvir tablet were evaluated comprehensively through in vivo drug screening on Drosophila, along with elemental composition analysis of Svarnvir tablets using atomic absorption spectroscopy (AAS), inductively coupled plasma-mass spectroscopy (ICP-MS), X-ray diffraction (XRD), and scanning electron microscopy energy dispersive spectroscopy (SEM-EDS). Results The Svarnvir tablet was found safe in Drosophila and their larvae up to the dosage of 1 mg/ml. In comparison to the control, morphologically and physiologically healthy and active flies were observed without any change in circadian locomotor activity rhythms or activity patterns. In addition, the elemental composition of Svarnvir tablets was evaluated using AAS, ICP-MS, and SEM-EDS, and the microstructure was examined by means of XRD and SEM. Conclusions Overall, these findings will contribute to an accessible and safe therapeutic approach for traditional age-old Ayurvedic medication to combat SARS-CoV-2 variants.

PMC11713176 (PMC) (EuropePMC)